Form D · Biotechnology
Loxo Oncology, Inc.
Stamford, CT · CIK 0001581720
Offering snapshot reported May 12, 2014 · SEC filing
- Reported sold
- $23.9M Offering amount: $23.9M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 24, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 12, 2014 | Initial | $23,888,747 | No comparison | 7 | SEC filing |
| Jul 18, 2013 | Initial | $10,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-217142
Series B Preferred Stock
Source: Form D, filed May 12, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James Barrett | Director |
| Joshua H. Bilenker | Director, Executive |
| David Bonita | Director |
| Steven Elms | Director |
| Keith Flaherty | Director |
| Dov Goldstein | Director |
| Avi Naider | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1 Landmark Square, Suite 1122
Stamford, CT, 06901
Stamford, CT, 06901